Clinical Trial Search

Primary: Change in Center for Epidemiologic Studies Depression (CES-D) Score From Baseline (Month 0) to Month 6 for the High Dose Cohort Versus Low Dose Cohort — -13.2982…

Primary: Percentage of Participants With Loss of Asthma Control — 40.5; 21.9; 27.0; 18.9 percentage of participants — p==0.0214

Primary: Maximum Tolerated Cell Dose (MTD) of Cluster of Differentiation 4 (CD4) Cells Transduced With an Anti-MAGE-A3-DP0401/0402 Restricted (MAGE-A3-DP4) T Cell Receptor and…

Primary: Percentage of Participants Achieving Clinical Response on the Clinical Global Impression (CGI) Scale — 75.0; 75.0 percentage of participants

Primary: Time to Viral Clearance — 16.0; 30.0 days — p=0.0415

Primary: Biochemical Response Rate Based on PSA — 3; 5 Participants

Primary: Sum of Pain Intensity Difference From 0 to 24 Hours (SPID24) Based on the 11 Point Numeric Pain Rating Scale — -96.80; -100.69; -74.96 score on a scale — p=0.0258

Primary: Progression Free Survival — 16.1 months

Primary: Percent Change From Baseline in Central Read Facial-Vitiligo Area Scoring Index (F-VASI) at Week 24 - Dose Ranging (DR) Period — -21.2; -21.2; -18.5; -14.6 Percent…

Primary: Percentage of Leukemic Stem Cells Present in Bone Marrow Aspirate Samples, in This Patient Population — 37.4; 2.32; 0.7; 7.04 percentage of leukemic stem cells

Primary: Frequency of Solicited AEs (Local and Systemic Reactions) Within 7 Days After Any Vaccination of the Primary Vaccination Series — 35; 31; 36; 32 events

Primary: 6 Month Progression Free Survival (PFS) — 2.8; NA Months

Primary: Change in SARS-COV-2 Viral Load — 6.5; 6.5; 4.4; 3.7 log10 copies/mL — p=0.06

Primary: Percent Change in D-dimer — -5.6; -2.4 percent daily change — p=0.24

Primary: Number of Participants With Solicited Local Reactions at the Injection Site (Pain, Tenderness, Erythema/Redness, Induration/Swelling) Recorded up to 7 Days After Each…